hello Bravo, interesting the question you asked ... my insignificant opinion is that, to receive an important "prize" from Barda, it is necessary to have political support or a big Pharma behind. For this reason I think that it isn't possible to obtain any significant contribution for Generex, and I also believe that the company has known this for months and that it is a reason why they have sought out lenders / partners abroad.

By the way, if I remember correctly, Moderna got more than 400 million from Barda ...
I have no precise idea of ​​how much it may cost to complete the research and testing process of a vaccine: certainly several hundred million ... And also for this reason I doubt that BK has the strength to finance the entire development. It may be / I hope that the Chinese have sufficient resources. .

Perhaps by making peptide test data public, and if these are as excellent as they appear, new lenders may be enticed to invest in Gnbt; moreover this could increase Ngio's valuation and be the springboard for Ngio's launch / listing

... .... hoping that the last month of the year will bring us the news we have been waiting for a long time .. Have a nice Sunday